Methods of treating anaemia
First Claim
Patent Images
1. A method of treating or reducing the risk of anaemia in a human, the method comprising administering an anti-target-of-interest (TOI) trap, antibody or antibody fragment to the human, wherein the TOI is selected from (a) to (h):
- (a) a bone morphogenetic protein 6 (BMP6) and the trap, antibody or antibody fragment specifically binds a human BMP6 encoded by a BMP6 nucleotide sequence comprising a SNP rs111588693; and
wherein the trap, antibody or antibody fragment comprises a human kappa chain constant region that comprises a Val at position 84 shown in SEQ ID NO;
93 or a Cys at position 87 shown in SEQ ID NO;
93 and wherein(i) the human comprises and expresses an IGKC1*01 human kappa chain constant region gene segment, or the human expresses antibodies comprising human kappa chain constant regions comprising a Val corresponding to position 84 shown in SEQ ID NO;
93 or a Cys at position 87 shown in SEQ ID NO;
93; and
(ii) said nucleotide sequence encoding the selected TOI, wherein the nucleotide sequence comprises said SNP.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.
122 Citations
29 Claims
-
1. A method of treating or reducing the risk of anaemia in a human, the method comprising administering an anti-target-of-interest (TOI) trap, antibody or antibody fragment to the human, wherein the TOI is selected from (a) to (h):
-
(a) a bone morphogenetic protein 6 (BMP6) and the trap, antibody or antibody fragment specifically binds a human BMP6 encoded by a BMP6 nucleotide sequence comprising a SNP rs111588693; and wherein the trap, antibody or antibody fragment comprises a human kappa chain constant region that comprises a Val at position 84 shown in SEQ ID NO;
93 or a Cys at position 87 shown in SEQ ID NO;
93 and wherein(i) the human comprises and expresses an IGKC1*01 human kappa chain constant region gene segment, or the human expresses antibodies comprising human kappa chain constant regions comprising a Val corresponding to position 84 shown in SEQ ID NO;
93 or a Cys at position 87 shown in SEQ ID NO;
93; and(ii) said nucleotide sequence encoding the selected TOI, wherein the nucleotide sequence comprises said SNP. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)
-
-
17. A method of treating or reducing the risk of anaemia in a human patient in need thereof, the improvement comprising administering an anti-target-of-interest (TOI) trap, antibody or antibody fragment to the human, wherein the TOI is selected from (a) to (h):
-
(a) a bone morphogenetic protein 6 (BMP6) and the trap, antibody or antibody fragment specifically binds a human BMP6 encoded by a BMP6 nucleotide sequence comprising a SNP rs111588693; and wherein the trap, antibody or antibody fragment comprises a human kappa chain constant region that comprises a Val at position 84 shown in SEQ ID NO;
93 or a Cys at position 87 shown in SEQ ID NO;
93 and wherein(i) the human comprises and expresses an IGKC1*01 human kappa chain constant region gene segment, or the human expresses antibodies comprising human kappa chain constant regions comprising a Val corresponding to position 84 shown in SEQ ID NO;
93 or a Cys at position 87 shown in SEQ ID NO;
93; and(ii) said nucleotide sequence encoding the selected TOI, wherein the nucleotide sequence comprises said SNP. - View Dependent Claims (18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)
-
Specification